• Home
• Collaborations
• Biopharmaceutical manufacturing

Biopharmaceuticals: Business profile

Our mission is to enable GSK and its customers to launch, supply and manage Biopharmaceutical products around the world.

We will use our experience and capabilities to deliver a diverse portfolio of biopharmaceutical products, maximizing value for GSK and its customers.

Full service provider

Our leading edge manufacturing facilities are designed for preparation and fill/finish of bulk biopharmaceutical products derived from mammalian, insect, and microbial cells.

The key elements of the facility are:

• Independent Cell Culture and Microbial Suites –mammalian and insect cell culture capacity at 10,000 litre (2x5,000L bioreactors) and microbial capacity at 20,000 litre (2 x 10,000L bioreactors)
• Independent Product Purification Suites - providing complete segregation of products
• Flexible clean room capacity
• Advanced monitoring and control of processes
• Testing Laboratories with a full array of testing capabilities and development - Microbial, Biological and Chemical
• cGMP Compliant Warehousing - for cell banks, raw materials and formulated bulk product
• Extensive Cold Storage Facilities
• Sample storage - including stability samples
• Fill/Finish Capability
• QC analytical/release testing in the US and EU

Manufacturing solutions

We provide all the advantages you need for a successful contract manufacturing partnership:

• Cost-effective commercial investment
• Considerable corporate resources
• Cost-effective operational scale
• Rapid development of products
• Highly experienced professionals
• Leading-edge facilities
• Tradition of innovation
• Proven operational excellence

Biopharm successes

• Proven track record of multiple successful technology transfers of both clinical and commercial products internally and externally
• FDA multi-product licensed facilities
• Proficient in supporting numerous biopharmaceutical technology platforms

Management biographies

Louise Duffy, PhD - VP & Site Director

Louise Duffy has held a number of positions of increasing responsibility across GSK before becoming VP and Site Director, Biopharmaceuticals. Prior to her current role, Louise was a Director in GSK's Worldwide Business Development group in which she was responsible for managing a portfolio of alliances ranging from early development through to commercial products. Prior to this, Louise has held a number of roles in Engineering before becoming the Director, Biopharmaceutical Technologies, responsible for technology transfer and scale-up of biopharmaceutical products into commercial manufacturing.

Before joining GSK, Louise worked for John Brown E&C in various Project Management and Process Engineering roles for both Capital and Process Development projects throughout North America and Europe. Prior to that Louise was head of Process Development for a start-up Biopharmaceutical and Vaccine venture (ABI Biotech) in Canada. Louise has lived and worked in the US, Canada, the UK, and Germany. Louise holds a Doctorate in Chemical Engineering from Imperial College, London, a Master's in Chemical Engineering (Imperial College), BSc (Hons) in Chemistry and Biochemistry (University of British Columbia, Canada).

Michael Maurer - Director, Operations

Mike has held positions of increasing responsibility at GSK and Merck. In his career, Mike has worked in both R&D and Manufacturing. He has specialized in biotechnology and has primarily worked with large scale operations. Mike has been directly involved with the start-up of multiple new biotech facilities including large scale microbial, live virus vaccine and large scale cell-culture. Mike has 20 years of commercial biotech manufacturing experience and 5 years in process development. In his current role at GSK, Mike is responsible for all aspects of Production as well as Facility Operations.

Joe Rogalewicz - Director, Quality Assurance

Joe Rogalewicz has over 20 years of Quality Assurance/Regulatory experience with emphasis in biological vaccine and therapeutic production and development. In his current role, Joe is responsible for the Quality Control and Quality Assurance activities for Biopharmaceuticals.

Barry Barton, PhD – Director, Biopharm Technology and New Product Introduction

Barry has over 25 years of experience in the development and utilization of biotechnology processes to manufacture both small and large molecule pharmaceuticals for commercial supply. Having joined the company in 1985 after completing a D.Phil. in Microbial Genetics he held a number of different technical roles both in the UK and US. In his current role, Barry leads the Biopharmaceutical Technology group and New Product introduction team.

Anthony (Tony) J Zuazo, CPA - Director, Finance

Tony is responsible for directing the Commercial activities of the Biopharmaceutical business, including the Financial, Business Development, and Procurement functions. Tony has over twenty years of experience with GSK, where he has supported three different divisions.